Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;1(4):399-409.
doi: 10.2147/nano.2006.1.4.399.

Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha

Heinz Zoller  1 , Wolfgang Vogel
Affiliations
Review

Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha

Heinz Zoller et al. Int J Nanomedicine. 2006.

Abstract

In immuno-competent individuals, the natural course of chronic hepatitis C virus (HCV) infection is highly variable and 5%-30% of patients develop cirrhosis over 20 years. Co-infection with HCV and human immunodeficiency virus (HIV) is an important prognostic factor and associated with more frequent and accelerated progression to cirrhosis. Until recently HIV/AIDS-related complications were life limiting in patients co-infected with HCV; the introduction of highly active antiretroviral treatment (HAART) and the better prognosis of HIV infection has made HCV-related complications an emerging health problem in HCV/HIV coinfected individuals. Treatment of chronic HCV infection has also evolved since the introduction of interferon-alpha. Recently, introduction of pegylated interferon-alpha (peginterferon-alpha) has resulted in an increase in sustained virus clearance rates of up to 80% in selected genotypes and patient populations. The safety and efficacy of modern anti HCV treatment regimens - based on peginterferon-alpha in combination with ribavirin - was evaluated in 4 controlled trials. Sustained clearance of hepatitis C virus can be achieved in up to 35% of patients with HIV/HCV co-infection, and novel HCV treatment regimens based on peginterferon-alpha have no negative effect on the control of HIV disease. In conclusion, if HIV infection is well controlled and CD4+ cell counts >100/mm3, treatment of chronic hepatitis C with peginterferon in combination with ribavirin is safe and should be given for 48 weeks regardless of the HCV genotype. Introduction of peginterferon-alpha has significantly improved adherence to treatment and treatment efficacy; in particular sustained virologic response in patients with HCV genotype 1 or 4 infection improved, but sustained viral clearance in only 7%-38% of patients infected with genotype I and 4 cannot be the final step in development of effective treatments in patients with HCV/HIV co-infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of ribavirin (left) and guanosine (right)
Figure 1A
Figure 1A
Ethyleneglycol monomer
Figure 1B
Figure 1B
Polyethylene glycol
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abonyi ME, Lakatos PL. Ribavirin in the treatment of hepatitis C. Anticancer Res. 2005;25:1315–20. - PubMed
    1. Akuta N, Suzuki F, Suzuki Y, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol. 2005;40:688–96. - PubMed
    1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–9. - PubMed
    1. Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. In: Terasaki PI, Cecka JM, editors. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory; 1996. pp. 15–30. - PubMed
    1. Bergamini A, Bolacchi F, Cepparulo M, et al. Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Clin Exp Immunol. 2001;123:459–64. - PMC - PubMed